Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00086593
First received: July 6, 2004
Last updated: April 16, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2005
  Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)